LAVA Therapeutics N.V. has announced that starting January 1, 2025, it will begin filing periodic reports and registration statements as a U.S. domestic issuer, adhering to the more detailed and prompt requirements compared to its previous status as a foreign private issuer. The company disseminates material information through various channels, including filings, press releases, public calls, its website, and social media accounts on LinkedIn, X, and YouTube. They advise the public to follow these channels as any information shared could be considered material.
Proper Names Mentioned: - LAVA Therapeutics N.V. - Fred Powell (Chief Financial Officer)